Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

159.97 +4.60 (+2.96%)
Streaming Delayed Price Updated: 11:04 AM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Industry Comparison: Evaluating Johnson &amp; Johnson Against Competitors In Pharmaceuticals Industry
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
Inovalon Unveils New Research, Products, and Solutions to Tackle Healthcare’s Most Complex Challenges 
From Inovalon Holdings, Inc.
Via GlobeNewswire
Comparative Study: Johnson &amp; Johnson And Industry Competitors In Pharmaceuticals Industry
Via Benzinga
Peering Into Johnson & Johnson's Recent Short Interest
Via Benzinga
Johnson & Johnson Unusual Options Activity
Via Benzinga
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support. 
Via Benzinga
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
Johnson & Johnson's Tremfya shows promising results in Phase 3 GRAVITI study for Crohn's disease, achieving significant clinical remission and endoscopic response at 48 weeks. 
Via Benzinga
3 Dividend Growth Stocks You Can Buy and Hold Forever
These healthcare stocks have fantastic dividend track records. 
Via The Motley Fool
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
Johnson & Johnson's Tremfya showed significant skin clearance in adults with low BSA moderate plaque psoriasis in the SPECTREM Phase 3b study, surpassing placebo. 
Via Benzinga
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
In 1980, around five dozen publicly traded companies held the highest possible credit rating (AAA) from Standard & Poor's. Today, there are only two left. 
Via The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
These three Vanguard ETFs are worth considering for the long term. 
Via The Motley Fool
Topics ETFs
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Fewer contenders means fewer constraints on expanding market share. 
Via The Motley Fool
Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability
The DOJ's U.S. Trustee Program seeks to dismiss Johnson & Johnson's third attempt to settle 60,000 talc lawsuits via bankruptcy, arguing the filing is a bad-faith strategy to avoid liability. 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
The activist investor says Pfizer has underperformed its peers and the broader market since 2019. 
Via Investor's Business Daily
What's Going On With Kenvue Stock Monday?
Kenvue Inc. (NYSE:KVUE) shares are moving higher Monday following a report suggesting activist investor Starboard Value has acquired a stake in the company. 
Via Benzinga
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
Elf Beauty appeared to rally along with KVUE on Monday. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump
Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge. 
Via Talk Markets
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
Starboard Value, an activist investor, has reportedly acquired a substantial stake in Kenvue Inc, the company behind popular consumer products like Tylenol and Listerine. 
Via Benzinga
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year
Investors looking for dividend stocks at reasonable valuations have come to the right place. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
These companies' longtime shareholders have generally been rewarded. 
Via The Motley Fool
Three Safe Dividend Kings to Weather Any Storm
Income investors should focus on stocks with solid yields, sustainable payouts, and strong business models. One way to achieve this is by investing in safe dividend kings. 
Via Talk Markets
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
Tyra Biosciences receives an upgrade from BofA, raising the price target to $31. The upgrade follows promising preclinical data for TYRA-300 and increased sales projections for metastatic urothelial... 
Via Benzinga
Stock Market Rally At Highs; Taiwan Semi, ASML, Netflix In Focus: Weekly Review
The Dow Jones and S&P 500 hit highs as they extended weekly win streaks. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
These stocks could deliver big over the long term. 
Via The Motley Fool
This Magnificent Dividend Stock Is as Healthy as It Gets
Johnson & Johnson's latest financial checkup shows it's still in excellent health. 
Via The Motley Fool
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated 2024 guidance reflects performance improvement but includes costs tied to... 
Via Benzinga
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
Healthcare giant and Dividend Aristocrat Johnson & Johnson is on track to hit new highs in 2025 and may sustain its rally well into 2026. 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?
Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.